Synovics Pharmaceuticals(OTC) SYVC

Synovics Pharmaceuticals, Inc. is a biotechnology company focused on the development, manufacture, and commercialization of generic over-the-counter (OTC) and prescription pharmaceutical products. Based in Fort Lauderdale, Florida, the company has been operational since 1983 and serves various drug stores, wholesalers, and distributors across the United States.

Products and Services

• Generic over-the-counter pharmaceutical products
• Prescription drug products
• Product categories include analgesics, cough, cold, and asthma relief

Growth Outlook

• Expansion into new OTC product categories is planned
• Increased demand for generic medications supports growth potential
• Strategic partnerships may enhance distribution capabilities

Financial Highlights

• Recent quarterly revenue of 1,578,332 reflects ongoing operations
• Trailing twelve months (TTM) gross profit margin stands at 34.56%
• Current ratio of 0.53 indicates liquidity management challenges

Synovics Pharmaceuticals, Inc. operates in a competitive sector, focusing on generic pharmaceuticals, which are increasingly in demand due to rising healthcare costs. The company's diverse product offerings in OTC and prescription categories position it well to capitalize on market trends. Recent financial data indicates a revenue of 1,578,332 for the latest quarter, showcasing the company's ability to generate sales despite challenges. The gross profit margin of 34.56% suggests that the company maintains a reasonable level of profitability relative to its sales. However, the current ratio of 0.53 highlights potential liquidity issues that may need addressing to ensure operational stability. Overall, Synovics Pharmaceuticals presents an intriguing opportunity for investors interested in the biotechnology sector, particularly in the generic pharmaceuticals market.